(Alliance News) - OptiBiotix Health PLC on Monday said it agreed a licence deal with Tata Chemicals Ltd to incorporate Tata's short-chain fructo-oligosaccharide Fossence into OptiBiotix's SlimBiome and LeanBiome products for the Indian market.
The York, England-based life sciences company develops edible compounds to tackle chronic conditions such as obesity and diabetes.
It shares were up 8.7% to 29.08 pence each in London on Monday morning.
OptiBiotix said Fossence will be a direct replacement for the fructo-oligosaccharide used in SlimBiome in other markets.
OptiBiotix also said Fossence brings "scientific substantiation of health benefits shown by fructo-oligosaccharide in the Indian market".
Tata Chemicals has approved the use of the Fossence logo on products containing SlimBiome in India, OptiBiotix added.
"Tata Chemicals is one of India's leading suppliers of food ingredients with many well-known and respected brands," said OptiBiotix Chief Executive Officer Stephen O'Hara.
"Fossence's established health benefits with Indian consumers and its trusted brand combined with SlimBiome's strong science, clinical studies, and excellent customer reviews will help reduce hunger and food cravings to support the weight management efforts of India's 135 million obese men and women."
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
OptiBiotix Health (OPTI)